New prognostic score based on clinical and biologic factors in patients <56 years with poor-risk MDS and AML treated with intensive treatment

被引：0
|
作者：
de Witte, T [1 ]
Oostetveld, M [1 ]
Suciu, S [1 ]
Muus, P [1 ]
Delforge, M [1 ]
Belhabri, A [1 ]
Aul, C [1 ]
Selleslag, D [1 ]
Ferrant, A [1 ]
Marie, J [1 ]
Amadori, S [1 ]
Jehn, U [1 ]
Mandelli, F [1 ]
Hess, U [1 ]
Helström-Lindberg, E [1 ]
Labar, B [1 ]
Willemze, R [1 ]
机构：
[1] Univ Nijmegen, Ctr Med, Nijmegen, Netherlands
来源：
BONE MARROW TRANSPLANTATION | 2005年 / 35卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S36 / S36
页数：1
相关论文
共 24 条
  • [1] Intensive chemotherapy followed by stem cell transplantation for patients with poor-risk mds and secondary AML (sAML).
    De Witte, T
    Suciu, S
    Verhoef, G
    Labar, B
    Archimbaud, E
    Aul, C
    Selleslag, D
    Ferrant, A
    Wijermans, P
    Mandelli, F
    Amadori, S
    Jehn, U
    Muus, P
    DeMuynck, H
    Dardenne, M
    Zittoun, R
    Willemze, R
    Gratwohl, A
    Apperley, J
    [J]. BLOOD, 1998, 92 (10) : 714A - 714A
  • [2] Disease-specific prognostic factors for outcome of patients with poor-risk Myelodysplastic syndromes (MDS) and acute myeloid leukemia, treated with intensive antileukemic therapy.
    Oosterveld, M
    Suciu, S
    Muus, P
    Delforge, M
    Belhabri, A
    Aul, C
    Selleslag, D
    Ferrant, A
    Marie, JP
    Amadori, S
    Jehn, U
    Mandelli, F
    Hess, U
    Helstrom-Lindberg, E
    Labar, B
    Beeldens, F
    Willemze, R
    De Witte, TM
    [J]. BLOOD, 2003, 102 (11) : 421A - 422A
  • [3] A new prognostic disease specific model to predict survival after intensive antileukemic treatment for young patients with poor-risk MDS and AML: Results of the CRIANT and AML-10 studies conducted by the EORTC/GIMENA/SAKK/HOVON/EBMT groups.
    Oosterveld, M
    Suciu, S
    Muus, P
    Delforge, M
    Belhabri, A
    Aul, C
    Selleslag, D
    Ferrant, A
    Marie, JP
    Amadori, S
    Jehn, U
    Hess, U
    Willemze, R
    Hellstrom-Lindberg, E
    Vignetti, M
    Labar, B
    Mandelli, F
    De Witte, T
    [J]. BLOOD, 2004, 104 (11) : 557A - 557A
  • [4] The prognostic impact of the presence of an HLA-identical donor on patients with high risk MDS and AML following MDS treated with an intensive antileukemic regimen
    Mattijssen, V
    DeWitte
    Suciu, S
    Boogaerts, M
    Labar, B
    Archimbaud, E
    Aul, C
    Selleslag, D
    Ferrant, A
    Weijermans, P
    Mandelli, F
    Amadori, S
    Jehn, U
    Muus, P
    DeMuynck, H
    Dardenne, M
    Willemze, R
    Gratwohl, A
    Apperley, J
    [J]. BLOOD, 1996, 88 (10) : 1908 - 1908
  • [5] AZACITIDINE TREATMENT OF HIGH RISK MDS AND AML, ANALYSIS OF LONG RESPONDING PATIENTS AND PROGNOSTIC FACTORS OF OVERALL SURVIVAL, CZECH MDS GROUP EXPERIENCE
    Jonasova, A.
    Cermak, J.
    Cervinek, L.
    Belohlavkova, P.
    Cerna, O.
    Kacmarova, K.
    Janousova, E.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S53 - S53
  • [6] The impact of cytogenetic features and clonality on the prognosis of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation:: A joint study of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups.
    de Witte, T
    Suciu, S
    van Dijk, J
    Delforge, M
    Hagemeijer, A
    Jotterand-Bellomo, M
    Tigaud, I
    Belhabri, A
    Aul, C
    Avaido, M
    Selleslag, D
    Schouten, H
    Ferrant, A
    Amadori, S
    Muus, P
    Anak, Ö
    Gratwohl, A
    Willemze, R
    [J]. BLOOD, 2000, 96 (11) : 546A - +
  • [7] Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups.
    de Witte, T
    Hagemeijer, A
    Suciu, S
    Delforge, M
    Jotterand-Bellomo, M
    Tigaud, I
    Belhabri, A
    Aul, C
    Avaido, M
    Schouten, H
    Ferrant, A
    Amadori, S
    Muus, P
    Anak, O
    Beeldens, F
    Jansen, J
    Hellstrom-Lindberg, E
    Gratwohl, A
    Willemze, R
    [J]. BLOOD, 2001, 98 (11) : 619A - 620A
  • [8] The prognostic impact of cytogenetic features and clonality of patients with poor risk MDS and secondary AML (sAML) after treatment with intensive chemotherapy and stem cell transplantation for the treatment; a joint study of the EORTC, EBMT, SAK, HOVO
    de Witte, T
    Suciu, S
    Delforge, M
    Hagemeijer, A
    Jotterrand-Bellomo, M
    Tigaud, I
    Belhabi, A
    Aul, C
    Avaido, M
    Selleslag, D
    Schouten, H
    Ferrant, A
    Amadori, S
    Muus, P
    Anak, O
    Gratwohl, A
    Willemze, R
    van Dijk, J
    [J]. BONE MARROW TRANSPLANTATION, 2001, 27 : S255 - S255
  • [9] The impact of post-remission therapy on outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy with or without stem cell transplantation in a joint study
    de Witte, T
    Hagemeijer, A
    Suciu, S
    Belhabri, A
    Delforge, M
    Aul, C
    Aivado, M
    Selleslag, D
    Schouten, H
    Runde, V
    Ferrant, A
    Kovacsovics, T
    Muus, P
    Jansen, J
    Beeldens, F
    Gratwohl, A
    Hess, U
    Helström-Lindberg, E
    Wijermans, P
    Ossenkoppele, G
    Marie, JP
    Willemze, R
    Amadori, S
    [J]. BONE MARROW TRANSPLANTATION, 2004, 33 : S2 - S2
  • [10] An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib
    Diaz-Beveridge, R.
    Bruixola, G.
    Lorente, D.
    Caballero, J.
    Rodrigo, E.
    Segura, A.
    Akhoundova, D.
    Gimenez, A.
    Aparicio, J.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (03): : 322 - 329
123